Healthily, also trading as Your.MD, has developed a mobile app that enables individuals and healthcare providers to monitor health issues via a machine learning symptom checker.
Founded in 2013, Healthily focuses on preventative care, with the aim of reducing unnecessary visits to healthcare professionals such as A&E or the GP surgery. The company has raised £51.0m, with Smedvig Capital and Reckitt Benckiser involved in multiple rounds.
Lifebit operates a cloud-based platform designed to enable researchers to work with sensitive health and genetic data directly where it is stored. It also uses AI to track diseases, discover new medicines, and analyse real-world health data, in accordance with privacy regulations
The London-based AI healthtech company has appeared on four high-growth lists — including BusinessCloud’s MedTech 50 2022 cohort — and has raised £52.1m in equity, as well as being awarded £27.8k worth of grants from InnovateUK.
Current Health is an Edinburgh-based healthtech company founded in 2014. The company specialises in remote patient monitoring and care-at-home solutions. Combining wearable devices with artificial intelligence, its products track vital signs and deliver actionable insights for healthcare providers.
Its platform enables clinicians to monitor patients’ health remotely, enabling early intervention and reducing hospital admissions. To date, the company has raised £54.0m in equity funding.
Numan is a healthtech company based in Camden, London, established in 2018. The company provides digital healthcare services focusing primarily on men’s health. It also offers personalised treatment plans and consultations through a proprietary platform.
The company has raised £56.6m in total funding, acquired Sweden-based AI healthtech company Vi-Health, and appeared on five high-growth lists. Numan’s latest £30m raise in 2022 has enabled the team to scale up development, headcount, and expand internationally.
Causaly has developed AI-based software designed to analyse large datasets for biomedical scientists and researchers. One of the younger healthtech companies to make our list, Causaly uses its technology to help identify genes present in diseases, which can assist with subsequent clinical drug development.
With £62.2m raised across four rounds, participants in the Camden healthtech company’s latest round of funding include Pentech Ventures, Index Ventures, and Greece-based Marathon Venture Capital.
The oldest company on our list, e-therapeutics offers a radically different approach to clinical drug development. Using a combination of computational power and biological data, the company accelerates drug development and treatments for complex diseases, including cancer.
A spinout from Newcastle University, e-therapeutics completed an IPO on the Alternative Investment Market (AIM) in 2007. In 2024, the company went private again, raising £19.7m to begin funding further development of its platform by integrating AI systems.
Established in 2017 and based in Lambeth, ZOE specialises in personalised nutrition. Using machine learning and biological data — including genomics and microbiome analysis — its app provides tailored dietary recommendations to users, with the aim of improving individual health outcomes.
ZOE has raised £89.9m across multiple funding rounds, with recent investments including a £11.7m fundraising in July 2024, backed by US-based fund Coefficient Capital. The company was featured on Deloitte’s Fast 50 high-growth list in 2024 and holds six patents in the United States for its innovative approaches to personalised health.
Founded in 2014 and based in Cambridge, Healx is a University of Cambridge spinout that develops AI-driven platforms for drug discovery, focusing on treatments for rare diseases. The company leverages machine learning to analyse disease-compound relationships, expediting the identification of potential therapies.
Healx has raised £90.3m across five funding rounds, including a £34.5m investment in August 2024 backed by Atomico, Balderton Capital, and a number of other venture capital investors, taking the company to third on our list.
Founded in 2013 and headquartered in Camden, BenevolentAI develops AI tools to accelerate drug discovery by analysing scientific data at scale. Like many other healthtech companies on this list, BenevolentAI uses these insights to focus on identifying novel drug targets and advancing precision medicine.
BenevolentAI has raised £253m across multiple funding rounds, including an £88.7m raise in 2019 and a subsequent £44.9m in 2020. In April 2022, the company was acquired by Odyssey Acquisition, and has since gone on to become a 10% scaleup.
Dundee-based Exscientia tops our list with £300m raised across seven rounds and over £5.40m awarded in grants.
The company, which was established in 2012, uses artificial intelligence to design and prioritise small molecule drugs for clinical development. It then predicts their potency and effects, providing indications of which molecules are most likely to make successful drugs.
The team at Exscientia have been exceptionally busy in recent years, making two strategic acquisitions — including Allcyte in 2021 — and completed a £226m IPO on the NASDAQ Stock Market in 2021.
